Atlas Trials

Palvella Therapeutics, Inc.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Palvella Therapeutics, Inc.

RecordFirmDate
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) (NCT07552077)Palvella Therapeutics, Inc.2026-04-01
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations (NCT06653842)Palvella Therapeutics, Inc.2024-12-20
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (NCT06239480)Palvella Therapeutics, Inc.2024-07-31
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations (NCT05050149)Palvella Therapeutics, Inc.2022-01-13
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (NCT05180708)Palvella Therapeutics, Inc.2021-11-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome (NCT04893486)Palvella Therapeutics, Inc.2021-05-06
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita (NCT04520750)Palvella Therapeutics, Inc.2020-09-01
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita (NCT03920228)Palvella Therapeutics, Inc.2019-04-01

Track Palvella Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.